A survey has shown that pharma companies have low confidence their rare disease medicines can launch in the UK.

For over 60 years the ABPI Code of Practice has been key to the UK industry’s self-regulation, and now, as pharma is experiencing its most intense period of change in decades, a new update seeks ...

The PMCPA is the independent body which administers the ABPI code, which covers the promotion of prescription medicines to UK health professionals and other relevant decision-makers, as well as ...

AstraZeneca, Moderna and Novo Nordisk have breached the Association of the British Pharmaceutical Industry (ABPI) Code of ...

The latest England action plan on rare diseases (published 28 February 2025) does not do enough to ensure NHS patients get access to potentially life-changing new medicines, according to the ...

Novo Nordisk breached clauses under the Association of the British Pharmaceutical Industry (ABPI) code of practice, according ...

The code covers the promotion of prescription medicines to health professionals and appropriate administrative staff. In addition, it sets the standard for the provision of information on medicines to ...

A new cross-industry report is calling for the UK’s NHS to design its health data infrastructure to meet the needs of pharma ...

To unlock the true potential of NHS data to improve population health, transform patient care and stimulate economic growth, England’s health data infrastructure must be designed to meet the needs of ...